Chimeric inhibitor molecules of complement activation
AssigneeOmeros Corporation
InventorsPeter Garred, Tina Hummelshoj Glue, Mikkel-Ole Skjodt
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel chimeric molecules of ficolin-associated polypeptides, such as fusion polypeptides for the use in the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombotic or coagulopathic related diseases. The present invention further relates to nucleic acid molecules encoding such fusion polypeptides, vectors and host cells used in the production of the fusion polypeptides.
Claims14
A method of treating a subject suffering from, or at risk for developing a condition associated with coagulation, thrombotic or a coagulopathic related disease or disorder comprising administering a composition comprising a chimeric molecule of a ficolin-associated polypeptide, wherein said chimeric molecule of a ficolin-associated polypeptide comprises:
- (a) a human ficolin-associated polypeptide comprising the amino acid sequence set forth in SEQ ID NO:1 or a variant thereof having at least 80% sequence identity to the amino acid sequence set forth in SEQ ID NO:1;
- and (b) and inhibitor of complement activation, and wherein said chimeric molecule inhibits complement activation to a subject suffering from a condition associated with coagulation, thrombotic or a coagulopathic related disease or disorder.
Dependencies are inferred from the claim text.